Vertex Pharmaceuticals Incorporated (VRTX) is listed on NasdaqGS in the Healthcare sector Β· Biotechnology industry. The current price is 556.15, down -0.11% from the previous close. Market cap is approximately $140.9B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
Vertex Pharmaceuticals Incorporated trades at a premium P/E of 32.43x, with a lot of growth priced in. A single quarter that misses consensus can compress the multiple sharply.
An ROE of 23.54% is well above the market average. Worth running a DuPont decomposition (margin Γ asset turnover Γ leverage) to check whether the high ROE is genuine or leverage-driven.
D/E of 9.77 indicates high leverage. Watch interest coverage and free cash flow closely, especially across rate cycles.
Vertex Pharmaceuticals Incorporated's 12.50% revenue growth signals strong momentum. The quality (price vs volume, new vs existing customers) determines whether it is sustainable.
Clinical trial outcomes, FDA decisions, and drug-pricing policy drive most of the short-term volatility.
Vertex Pharmaceuticals Incorporated is near its 52-week high (560.25), in the top 2% of the range. Prices close to new highs invite two readings β little overhead supply, or stretched expectations β and volume is the usual tiebreaker.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
The stock moved within a 1.57% high-to-low band on the day, closing -0.11%. That falls within a typical intraday range.
Vertex Pharmaceuticals Incorporated (VRTX) is listed on NasdaqGS, with recent volume of 232,979 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.